<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123770</url>
  </required_header>
  <id_info>
    <org_study_id>ESNDBCP</org_study_id>
    <nct_id>NCT03123770</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients</brief_title>
  <acronym>ESNDBCP</acronym>
  <official_title>The Efficacy and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel in Breast Cancer Patients: A Multicentric, Open-label, Non-randomized Concurrent Control, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical Univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentric, open-label,non-randomized concurrent control, 1:1
      match,non-inferiority trial that assesses the efficacy and safety of neoadjuvant chemotherapy
      regimen DC-T and EC-T in breast cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Determine the efficacy and safety of neoadjuvant chemotherapy regimen DC-T and
      EC-T in suitable breast cancer patients.

      Participants are randomized to 1 of 2 treatment arms.

        1. Arm I: Participants receive pegylated liposomal doxorubicin plus cyclophosphamide
           followed by docetaxel before surgery.

        2. Arm II: Participants receive epirubicin plus cyclophosphamide followed by docetaxel
           before surgery.

      Patients in arms I and II will undergo physical examination, MRI, estimating of side effects
      every 4 cycles referring to RECIST (Response Evaluation Criteria In Solid Tumor) guideline.
      To adjust for potential bias, patients in DC-T arm were matched 1:1 to patients in the EC-T
      arm based on Her-2 and ER status. After finishing 8 cycles of neoadjuvant chemotherapy, every
      patient will receive mastectomy or breast-conserving surgery and then assess the pCR rate of
      primary lesion and axillary lymph nodes. Adjuvant radiotherapy and endocrine therapy will be
      taken if necessary. Every patient will be followed-up for five years to monitor survival
      condition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>5 years</time_frame>
    <description>The pathological complete response rate of primary lesion and axillary lymph nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>5 years</time_frame>
    <description>Determine side effects of these drugs like cardiotoxicity ,hematological toxicity，gastrointestinal symptoms and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Determine the overall survival at 5 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>DC Follow T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC Follow T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>a new kind of doxorubicin</description>
    <arm_group_label>DC Follow T</arm_group_label>
    <other_name>PLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>traditional chemotherapy drug</description>
    <arm_group_label>DC Follow T</arm_group_label>
    <arm_group_label>EC Follow T</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>traditional chemotherapy drug used in breast cancer</description>
    <arm_group_label>EC Follow T</arm_group_label>
    <other_name>E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>traditional chemotherapy drug used in breast cancer</description>
    <arm_group_label>DC Follow T</arm_group_label>
    <arm_group_label>EC Follow T</arm_group_label>
    <other_name>T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged : 18~70 years.

          2. WHO (ECOG) performance status 0-2.

          3. Patients who have read and understand the informed consent form and have given written
             informed consent.

          4. Diagnosed as invasive breast cancer by core biopsy

          5. Diagnosed pre-surgically as (cTNM Staging)Stage II-III and suit for neoadjuvant
             chemotherapy.

          6. Patients had previously not received chemotherapy，radiotherapy or biotherapy.

          7. Normal organ function，meeting the requirement of laboratory testing below:

               -  WBC≥4.0×109/L,

               -  NEU≥1.5×109/L,

               -  PLT≥100×109/L,

               -  HB ≥10g/dL,

               -  Scr≤1.5× ULN,

               -  AST ≤2.5×ULN,

               -  ALT ≤2.5×ULN,

               -  TDIL≤1.5×ULN.

          8. Patients with measurable lesion assessed by imaging using the RECIST (Response
             Evaluation Criteria In Solid Tumor) guideline，（long diameter of primary lesion ≥1cm or
             minor diameter of lymph node ≥1.5cm）；

        Exclusion Criteria:

          1. Pregnant or lactating women were excluded.

          2. History of receiving organ transplantation（including Autologous bone marrow
             transplantation and peripheral hematopoietic stem-cell transplantation).

          3. Dysfunction of peripheral nerve system caused by other diseases or history of either
             severe mental disorder or central nervous system disorders.

          4. Uncontrolled infection or severe peptic ulcer need treatment.

          5. Severe hepatic disease（such as hepatic cirrhosis),nephrosis,respiratory disease or
             uncontrolled diabetes.

          6. Patients with malignancies (other than breast cancer) within the last 5 years, except
             for adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the
             skin.

          7. Significant abnormal EKG or cardiac disease with drastic symptoms like congestive
             heart failure or severe coronary disease or uncontrolled arrhythmia or myocardial
             infarction within 12 months or NYHA level III-IV or LVEF&lt;55% .

          8. Be allergic to test drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Jian, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital of Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huang Jian, Dr</last_name>
    <phone>8657187315009</phone>
    <email>drhuangjiang@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Zhigang, Dr</last_name>
    <phone>8657187315009</phone>
    <email>zzg2011@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer institute</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Zhigang, Dr</last_name>
      <phone>8657187315009</phone>
      <email>zzg2011@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9.</citation>
    <PMID>14998846</PMID>
  </reference>
  <reference>
    <citation>Vici P, Pizzuti L, Gamucci T, Sergi D, Conti F, Zampa G, Del Medico P, De Vita R, Pozzi M, Botti C, Di Filippo S, Tomao F, Sperduti I, Di Lauro L. Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients. J Cancer. 2014 Apr 25;5(6):398-405. doi: 10.7150/jca.9132. eCollection 2014.</citation>
    <PMID>24847380</PMID>
  </reference>
  <reference>
    <citation>Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.</citation>
    <PMID>25981896</PMID>
  </reference>
  <reference>
    <citation>Uriarte-Pinto M, Escolano-Pueyo Á, Gimeno-Ballester V, Pascual-Martínez O, Abad-Sazatornil MR, Agustín-Ferrández MJ. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer. Int J Clin Pharm. 2016 Apr;38(2):446-53. doi: 10.1007/s11096-016-0278-5. Epub 2016 Mar 7.</citation>
    <PMID>26951122</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Zhigang Zhang</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Pegylated liposomal doxorubicin</keyword>
  <keyword>PLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

